Loading clinical trials...

Anticoagulation in Patients With Venous Thromboembolism and Cancer | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Anticoagulation in Patients With Venous Thromboembolism and Cancer

VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)

NCT04618913•Pfizer

Summary

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A VTE diagnosis
•Active cancer or history of cancer
•Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
•Age ≥ 18 years at the date of index VTE (Venous thromboembolic)

Exclusion Criteria

•Prior VTE diagnosis
•Diagnosis of prior atrial fibrillation
•Inferior Vena Cava (IVC) filter
•Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
•Pregnancy
•More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
•Patients with less than one day of follow up

Locations (1)

Pfizer Investigational Site

London, United Kingdom

Key Dates

Start Date

December 14, 2020

Primary Completion Date

April 6, 2026

Completion Date

April 6, 2026

Last Updated

March 12, 2026

Enrollment

ACTUAL participants

Conditions

NeoplasmsEmbolism

Interventions

Apixaban

DRUG

Rivaroxaban

DRUG

Edoxaban

DRUG

Dabigatran

DRUG

VKA

DRUG

LMWH

DRUG

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851

NauseaVomiting+2 more

View study

RECRUITINGNA

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

NCT07159659

Thoracic Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies